Helex is pioneering a paradigm shift in the treatment of chronic and rare kidney disorders by developing programmable non-viral lipid nanoparticle (LNP) therapeutics that deliver therapeutic cargo ...

Helex has raised $3.5m in an oversubscribed seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney diseases. The round saw participation from SOSV, Bluehill ...

Therapeutics Startup Helex Secures USD 3.5 Mn to Develop Targeted Kidney Treatments Helex, a therapeutics startup focused on genetic kidney diseases, has raised USD 3.5 million in a seed funding round ...

Biotechnology startup Helex on Thursday raised $3.5 million in a funding round led by pi Ventures, with participation from Bluehill Capital, SOSV, and a group of global investors, to advance the ...

Hyderabad- and US-based biotech startup Helex has raised $3.5 million in a seed round led by pi Ventures, with participation from Bluehill Capital, SOSV, and other global investors. The startup is ...

May 31, 2007 (Seattle, WA) - The pivotal trial of a new device approved for the percutaneous closure of atrial septal defects (ASD)--the HELEX septal occluder (WL Gore and Associates, Flagstaff, ...

Chennai-based early-stage venture capital firm BlueHill VC has invested in Hyderabad-based startup Helex, which is developing advanced therapeutics for the needs of patients with genetic kidney ...

Helex, a therapeutics company developing a new class of targeted medicines for genetic kidney diseases, today announced its oversubscribed $3.5 million Seed round, led by pi Ventures, with ...

Helex, a US and India based therapeutics startup developing a new class of targeted medicines for genetic kidney diseases, today announced its oversubscribed $3.5 million Seed round, led by pi ...